Tempus Introduces Fuses, A Program Designed to Transform Therapeutic Research and Build the Largest Diagnostic Platform Using its Novel Foundation Model
Over the past decade, Tempus has built a multimodal data library of over 40 million research records, including more than 1.5 million records with matched clinical data linked with genomic information, 2 million records with imaging data, and approximately 300,000 records with genomic and whole transcriptomic data. The scale and size of this data library will allow the company to uncover groundbreaking discoveries that were previously out of reach.
Fuses will accelerate Tempus' comprehensive testing portfolio, expanding its suite of AI-enabled diagnostics. Insights from Fuses will be developed into clinically validated algorithmic diagnostics that may enable highly personalized care, such as identifying patients unlikely to respond to approved therapies or those at risk of severe treatment-related events. Tempus has already begun this work with last year's launch of its Immune Profile Score (IPS) a multimodal biomarker that can be used as a prognostic indicator for adult patients with metastatic pan-solid tumors eligible for immune checkpoint inhibitor (ICI)-based therapy.
'We have spent the last ten years building, scaling, and curating one of the most comprehensive datasets in our industry, and now we are well positioned to develop the world's largest diagnostic model, designed to answer critical, unsolved questions and make our diagnostics smarter and more personalized,' said Eric Lefkofsky, Founder and CEO of Tempus. 'We are on the brink of delivering tangible, transformative change in matching the right therapies to the right patients - making personalized care a reality for millions.'
The foundational model behind Fuses is learning generalizable rules determining prognosis and drug benefit in real-world practice. With the goal of furthering researchers' understanding of why certain clinical trials fail, identify new indications for investigational drugs, optimize trial design, and uncover combination therapies to broaden patient benefit. By revealing biomarker rules, the model may also surface mechanisms of drug response and resistance to inspire a new generation of companion diagnostics and therapeutic research.
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the potential impact of Fuses and its insights in oncology clinical care and therapeutic research and discovery, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.
You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
21 minutes ago
- Business Wire
ScienceSoft Raises the Bar for AI Voice Scheduling in Healthcare
MCKINNEY, Texas--(BUSINESS WIRE)--Human-Like, Real-Time AI Scheduler launched by ScienceSoft ScienceSoft's AI assistant processes 70% more scheduling requests per hour than a human and reduces booking time by 40%. Share ScienceSoft has introduced a HIPAA-compliant AI scheduling assistant that enables natural, human-like conversations with patients. Built on the first-ever integration of Amazon's Nova Sonic speech-to-speech model and the LiveKit Media Server, the assistant supports real-time voice interaction and seamless data exchange with hospital systems. What sets the assistant apart is how it communicates. Most voice agents process speech in separate steps, which slows down the conversation and makes it sound robotic. The model behind our agent is the first to support bidirectional streaming through a single API, enabling listening and responding in real time without delays or awkward pauses. So, the patients get a whole new level of experience. They speak normally and get a timely, helpful response, without the friction they've come to expect from automated systems. The system handles both incoming and outgoing calls, verifies patient identity, checks provider availability, and updates hospital systems during the call. Integration with EHR, CRM, and practice management platforms ensures appointments are confirmed or changed on the spot, without follow-up. The scheduler runs in a secure, HIPAA-compliant cloud environment and is monitored with tools like Amazon Bedrock Guardrails and AWS Macie. Our estimations show the agent can potentially reduce appointment booking time by 40%, cut call abandonment rates by 30%, and lower operational costs by at least 50%. As it can handle multiple calls simultaneously, it is expected to process 70% more calls per hour than a patient service representative. Looking for Insider IT Info? ScienceSoft experts are ready to share practical insights into healthcare technology and patient-facing solutions. Learn how technology is reshaping the way providers interact with patients.
Yahoo
21 minutes ago
- Yahoo
Nvidia Stock One of the Best to Own in Q3
Nvidia Corp (NASDAQ:NVDA) just became the world's most valuable company in history. The shares hit a record high of $160.98 today, up 19.1% since the start of 2025. For those betting on even more highs for the , it's worth noting that the stock rarely disappoints in the third quarter. Per Schaeffer's Senior Quantitative Analyst Rocky White, NVDA finished the third quarter positive in eight out of the last 10 years, making it one of the best S&P 500 Index (SPX) stocks to own during this time. For the three-month period, the equity has averaged a 14.4% return, and another move of this magnitude from today's peak would put the shares at $184.16. Now looks like a good time to weigh in with options, too. NVDA's Schaeffer's Volatility Index (SVI) of 32% ranks in the low 1st percentile of its annual range, meaning options traders are pricing in low volatility expectations. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
25 minutes ago
- Business Wire
SOSi Wins $260 Million DEA Contract for Foreign Language Support
RESTON, Va.--(BUSINESS WIRE)-- SOSi announced today that the United States Drug Enforcement Administration (DEA) awarded the company a contract valued at approximately $260 million to provide foreign language support for its Title III electronic surveillance program. SOSi will support 241 offices across the United States, delivering the monitoring, transcription, translation, interpretation, validation, and analysis of lawfully intercepted communications. 'This contract expands SOSi's partnership with DEA, allowing us to further support the agency's critical mission of enforcing controlled substance laws and regulations,' said Steve Iwicki, SOSi Senior Vice President for Intelligence Solutions. 'SOSi's expertise bolsters DEA's efforts to reduce the devastating impact illicit substances have on our nation.' SOSi has been supporting the federal law enforcement agencies' Title III programs since the company's inception in 1989. Its first federal contract was with the DEA's New York Field Office in 1989. In 2021, SOSi was awarded a similar contract to provide the same services to the Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF). In 2023, the DEA awarded SOSi a contract to provide language analytic support to its Special Operations Division. 'We're excited to continue our 35-year legacy of supporting the DEA's mission through this nationwide Title III language services contract,' said Julian Setian, CEO of SOSi. 'This award reflects not only our deep-rooted partnership with the DEA, but also our unmatched expertise in managing highly sensitive lawful intercept programs for the U.S. law enforcement community. Over the next year, we plan to introduce our proprietary Pandion system to the federal law enforcement agencies, which leverages AI to process and analyze intercepted communications and exemplifies our commitment to innovation in support of national security and law enforcement operations.' ABOUT SOSi Founded in 1989 and headquartered in Reston, Virginia, SOSi is a private defense and government services firm that is principally engaged in the research, design, development, integration, sustainment, and delivery of advanced technology systems, products, and services. Its capabilities include data science, software development, network engineering, intelligence, surveillance, and reconnaissance (ISR), and logistics.
